Use of diuretics in heart failure and cirrhosis

Seminars in Nephrology

Volumn 31, Issue 6, 2011, Pages 503-512

  Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Ascites; Edema; Secondary hyperaldosteronism

Indexed keywords

ALBUMIN; ALDOSTERONE; AMILORIDE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; LIXIVAPTAN; METOLAZONE; MIDODRINE; PLACEBO; POTASSIUM ION; PROPRANOLOL; RENIN; SODIUM CHLORIDE COTRANSPORTER; SODIUM ION; SPIRONOLACTONE; TERLIPRESSIN; TOLVAPTAN; WATER;

ARTERY DILATATION; ARTICLE; ASCITES; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG UTILIZATION; EDEMA; ESOPHAGUS SURGERY; ESOPHAGUS VARICES BANDING; ESOPHAGUS VARICES BLEEDING; GYNECOMASTIA; HEART ARRHYTHMIA; HEART FAILURE; HEART OUTPUT; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LUNG CONGESTION; MASTALGIA; METABOLIC ALKALOSIS; MICTURITION; MORBIDITY; MORTALITY; PARACENTESIS; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PORTAL HYPERTENSION; PRESSORECEPTOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SODIUM RETENTION; SYMPATHETIC TONE; THIRST; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; WATER RETENTION;

ASCITES; DIURETICS; EDEMA; HEART FAILURE; HUMANS; LIVER CIRRHOSIS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 81355153913     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.09.005     Document Type: Article

References (44)

1. Henry J.P., Gauer O.H., Reeves J.S. Evidence of atrial location of receptors in influencing urine flow. Circ Res 1956, 4:85-90.
2. Linden R.J., Kappagoda C.T. Atrial receptors 1982, Cambridge University Press, Cambridge.
3. Clinical physiology series. Atrial hormones and other natriuretic factors 1987, American Physiological Society, Bethesda, MD. P.J. Mulrow, R.W. Schrier (Eds.).
4. Schrier R.W. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med 1990, 113:155-159.
5. Bansal S., Lindenfeld J.A., Schrier R.W. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?. Circ Heart Fail 2009, 2:370-376.
6. Myers B.D., Deen W.M., Brenner B.M. Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat. Circ Res 1975, 37:101-110.
7. Schrier R.W., DeWardener H.E. Tubular reabsorption of sodium ion: influence of factors other than aldosterone and glomerular filtration rate. N Engl J Med 1971, 285:1292-1303.
8. Schrier R.W., Better O.S. Peripheral arterial vasodilation hypothesis: implications for impaired aldosterone escape. Eur J Gastroenterol Hepatol 1991, 3:721-729.
9. Szatalowicz V.I., Arnold P.E., Chaimovitz C., Bichet D., Berl T., Schrier R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981, 305:263-266.
10. Bichet D., Szatalowicz V., Chaimovitz C., Schrier R.W. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982, 96:413-417.
11. Kozak L.J., Owings M.F., Hall M.J. National Hospital Discharge Survey: 2002 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2005, 158:1-199. National Center for Health Statistics.
12. Gheorghiade M., Filippatos G. Reassessing treatment of acute heart failure syndromes: the ADHERE registry. Eur Heart J 2005, 7(Suppl B):B131-B139.
13. Adams K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations form the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). Am Heart J 2005, 149:209-216. ADHERE Scientific Advisory Committee and Investigators.
14. Gheorghiade M., Filippatos G., De Luca L., Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am J Med 2006, 119:S3-S10.
15. Schrier R.W. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?. J Am Coll Cardiol 2006, 47:1-8.
16. Heywood J.T., Fonarow G.C., Costanco M.R., et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007, 13:422-430. ADHERE Scientific Advisory Committee and Investigators.
17. Schrier R.W., Masoumi A., Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010, 5:1132-1140.
18. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999, 341:709-717. Randomized Aldactone Evaluation Study Investigators.
19. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996, 78:902-907. The RALES Investigators.
20. Pitt B., Bakris G., Ruilope L.M., DiCarlo L., Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008, 118:1643-1650. EPHESUS Investigators.
21. Abdallah J.G., Schrier R.W., Edelstein C., Wyse B., Ellison D. Loop diuretic infusion increases thiazide-sensitive Na+-Cl- cotransporter abundance: role of aldosterone. J Am Soc Nephrol 2001, 12:1335-1341.
22. Fauchauld P. Effects of ultrafiltration of body fluid and transcapillary colloid osmotic gradient in hemodialysis patients, improvements in dialysis therapy. Contrib Nephrol 1989, 74:170-175.
23. Schrier R.W. How to use diuretics in heart failure patients. Heart failure: a practical approach to therapy 2007, 91-104. McGraw-Hill Medical Publishing Division, New York. W. Abraham, H. Krum (Eds.).
24. Schrier R.W. Hyperkalemia: a threat to RAAS inhibition?. Nat Rev Nephrol 2010, 6:245-246.
25. Juurlink D., Mamdani M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
26. Li W., Struthers A.D., Fahey T., Watson A.D., MacDonald T.M. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010, 340:c1768.
27. Braunwald E., Plauth W., Morrow A.G. A method for the detection and quantification of impaired sodium excretion. Results of an oral sodium tolerance test in normal subjects and in patients with heart disease. Circulation 1965, 32:223-231.
28. van Vliet A.A., Donker A.J., Nauta J.J., Verheugt F.W. Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 1993, 71:21A-28A.
29. Hensen J., Abraham W.T., Durr J.A., Schrier R.W. Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 1991, 11:441-446.
30. Verbalis J.G., Goldsmith S.R., Greenberg A., Schrier R.W., Sterns R.H. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007, 120:S1-S21.
31. Schrier R.W., Gross P., Gheorghiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112. SALT Investigators.
32. Berl T., Quittnat-Pelletier F., Verbalis J., et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010, 21:705-712. SALTWATER Investigators.
33. Arroyo V., Bosch J., Gaya-Beltran J., et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981, 94:198-201.
34. Salerno F., Gerbes A., Gines P., Wong F., Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007, 56:1310-1318.
35. Ginès A., Escorsell A., Ginès P., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:229-236.
36. Schrier R.W., Arroyo V., Bernardi M., Epstein M., Henricksen J.H., Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988, 8:1151-1157.
37. Martin P.-Y., Ohara M., Gines P., et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998, 101:235-242.
38. Gregory P.B., Broekelschen P.H., Hill M.D., et al. Complications of diuresis in the alcoholic patient with ascites: a controlled trial. Gastroenterology 1977, 73:534-538.
39. Ginès P., Schrier R.W. Renal failure in cirrhosis. N Engl J Med 2009, 361:1279-1290.
40. Moore K.P., Wong F., Ginès P., et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003, 38:258-266.
41. Gonwa T.A., Klintmalm G.V., Levy M., Jennings L.S., Goldstein R.M., Husberg B.S. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995, 59:361-365.
42. Gerbes Al, G°lberg V., Ginès P., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124:933-939.
43. Arroyo V., Ginès P., Gerbes A.L., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996, 23:164-176.
44. Garcia-Pagán J.C., Caca K., Bureau C., et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010, 362:2370-2379.